BFC Planning’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$583K Buy
5,283
+801
+18% +$77.4K 0.02% 548
2026
Q2
$351K Sell
4,482
-614
-12% -$41.9K 0.01% 739
2026
Q1
$329K Sell
5,096
-1,046
-17% -$73.7K 0.01% 696
2025
Q4
$413K Buy
6,142
+187
+3% +$12.6K 0.02% 606
2025
Q3
$437K Buy
5,955
+664
+13% +$44.1K 0.03% 419
2025
Q2
$275K Sell
5,291
-51
-1% -$2.9K 0.02% 516
2025
Q1
$341K Buy
5,342
+531
+11% +$30.8K 0.03% 432
2024
Q4
$230K Buy
4,811
+224
+5% +$11.5K 0.02% 559
2024
Q3
$263K Buy
+4,587
New +$263K 0.02% 526

Other funds holding HALO

BFC Planning's HALO Position: Q3 2026 in Review

BFC Planning increased its Halozyme (HALO) stake by 18% in Q3 2026, buying an estimated $77.4K and bringing the position to 5,283 shares worth $583K. The position accounts for 0.02% of the portfolio, ranked #548.

BFC Planning first reported a position in HALO in Q3 2024 and has held it in 9 quarters since. 636 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • BFC Planning held 5,283 shares of Halozyme worth $583K as of Q3 2026.
  • BFC Planning bought 801 Halozyme shares in Q3 2026, an estimated $77.4K.
  • Halozyme made up 0.02% of BFC Planning's portfolio in Q3 2026, its #548 holding.
  • BFC Planning first reported a position in Halozyme in Q3 2024 and has held it in 9 quarters since.
  • 636 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.